Who
Christopher B. Prentiss
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, MannKind; Chief Financial Officer, Adamas Pharmaceuticals.
In numbers
- Trades disclosed
- 43
- Buys
- 0
- Sells
- 9
- Bought
- $0
- Sold
- $96K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 6 Oct 2017
- Last trade
- 15 Jul 2026
- Last filed
- 17 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Jul 2026filed 17 Jul 2026 | MNKD MannKindPharmaceuticals | SEC FORM 4 Code F | $47K11,572 at $4.09 | filing |
| 15 Jul 2026filed 17 Jul 2026 | MNKD MannKindPharmaceuticals | SEC FORM 4 Code F | $44K10,675 at $4.09 | filing |
| 15 Jul 2026filed 17 Jul 2026 | MNKD MannKindPharmaceuticals | SEC FORM 4 Code F | $47K11,572 at $4.09 | filing |
| 15 Jul 2026filed 17 Jul 2026 | MNKD MannKindPharmaceuticals | SEC FORM 4 Code F | $44K10,675 at $4.09 | filing |
| 22 Apr 2026filed 24 Apr 2026 | MNKD MannKindPharmaceuticals | SEC FORM 4 Code F | $34K12,267 at $2.74 | filing |
| 22 Apr 2026filed 24 Apr 2026 | MNKD MannKindPharmaceuticals | SEC FORM 4 Code F | $34K12,267 at $2.74 | filing |
| 23 Mar 2026filed 25 Mar 2026 | MNKD MannKindoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —221,000 at $0.00 | filing |
| 23 Mar 2026filed 25 Mar 2026 | MNKD MannKindoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —217,000 at $0.00 | filing |
| 23 Mar 2026filed 25 Mar 2026 | MNKD MannKindoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —221,000 at $0.00 | filing |
| 23 Mar 2026filed 25 Mar 2026 | MNKD MannKindoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —217,000 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | MNKD MannKindPharmaceuticals | SEC FORM 4 Code A | $16K5,000 at $3.27 | filing |
| 1 Mar 2026filed 3 Mar 2026 | MNKD MannKindPharmaceuticals | SEC FORM 4 Code A | $16K5,000 at $3.27 | filing |
| 15 Jul 2025filed 17 Jul 2025 | MNKD MannKindPharmaceuticals | SEC FORM 4 Code F | $44K11,540 at $3.85 | filing |
| 13 May 2025filed 15 May 2025 | MNKD MannKindoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —145,000 at $0.00 | filing |
| 13 May 2025filed 15 May 2025 | MNKD MannKindPharmaceuticals | SEC FORM 4 Code A | —119,000 at $0.00 | filing |
| 15 May 2024filed 28 Mar 2025 | MNKD MannKindPharmaceuticals | SEC FORM 4 Code A | —103,600 at $0.00 | filing |
| 15 May 2024filed 17 May 2024 | MNKD MannKindoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —158,000 at $0.00 | filing |
| 15 May 2024filed 17 May 2024 | MNKD MannKindPharmaceuticals | SEC FORM 4 Code A | —103,600 at $0.00 | filing |
| 15 May 2024filed 17 May 2024 | MNKD MannKindPharmaceuticals | SEC FORM 4 Code A | —129,000 at $0.00 | filing |
| 24 Nov 2021filed 24 Nov 2021 | Adamas Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —37,500 | filing |
News
No headline names them, or the companies they trade most, lately.